Clinical Trials Browser

Phase 1/2 × Unknown × regorafenib × Clear all

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT05426811 2022-06-29

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04110093 2020-12-30

Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT03946917 2020-05-12

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04008511 2019-07-05

Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms